Parallax Volatility Advisers
ADMS

Parallax Volatility Advisers’s Adamas Pharmaceuticals ADMS Stock Holding History

Parallax Volatility Advisers’s Portfolio ADMS Stock Details ADMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-33,700
Closed -$870K – 3889
2018
Q2 		$870K Buy
+33,700
New +$933K ﹤0.01% 1130
2017
Q4 		– Sell
-10,000
Closed -$212K – 5195
2017
Q3 		$212K Buy
+10,000
New +$183K ﹤0.01% 1458

Other funds holding ADMS

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $4.25B AUM 141.71% 1-Year Est. Return

Parallax Volatility Advisers's ADMS Position: Q1 2019 in Review

Parallax Volatility Advisers sold out of Adamas Pharmaceuticals (ADMS) in Q1 2019, closing a stake of 6,000 shares — an estimated $51K sold.

Parallax Volatility Advisers first reported a position in ADMS in Q4 2017 and held it in 4 quarters. The position peaked at $91K in Q4 2017. 99 funds tracked by Wall St. Rank hold ADMS as of Q1 2019.

  • Parallax Volatility Advisers reported no remaining Adamas Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Parallax Volatility Advisers sold 6,000 Adamas Pharmaceuticals shares in Q1 2019, an estimated $51K.
  • Parallax Volatility Advisers first reported a position in Adamas Pharmaceuticals in Q4 2017 and held it in 4 quarters.
  • Parallax Volatility Advisers's Adamas Pharmaceuticals position peaked at $91K in Q4 2017.
  • 99 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q1 2019.

Based on Parallax Volatility Advisers's 13F filing for Q1 2019, filed 15 May 2019.